Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential
Authors:
- 8 January 2010
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 14 (2) , 207-219
Abstract
(2010). Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opinion on Therapeutic Targets: Vol. 14, No. 2, pp. 207-219.Keywords
This publication has 90 references indexed in Scilit:
- Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following ProstatectomyClinical Cancer Research, 2008
- Intra‐neural administration of fractalkine attenuates neuropathic pain‐related behaviourJournal of Neurochemistry, 2008
- Fractalkine Deficiency Markedly Reduces Macrophage Accumulation and Atherosclerotic Lesion Formation in CCR2 −/− MiceCirculation, 2008
- CX3CR1 Is Expressed by Prostate Epithelial Cells and Androgens Regulate the Levels of CX3CL1/Fractalkine in the Bone Marrow: Potential Role in Prostate Cancer Bone TropismCancer Research, 2008
- Neuronal Chemokines: Versatile Messengers In Central Nervous System Cell InteractionMolecular Neurobiology, 2007
- Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkineBrain, Behavior, and Immunity, 2007
- Inhibition of spinal microglial cathepsin S for the reversal of neuropathic painProceedings of the National Academy of Sciences, 2007
- The chemokine CX3CL1/fractalkine interferes with the antinociceptive effect induced by opioid agonists in the periaqueductal grey of ratsBrain Research, 2007
- The neurotrophic factor artemin influences the extent of neural damage and growth in chronic pancreatitisGut, 2007
- Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancerGut, 2006